We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $12.4B
1-Year Est. Return 64.17%
This Fund
S&P 500
This Quarter Est. Return
+5.47%
1 Year Est. Return
+64.17%
3 Year Est. Return
+130.04%
5 Year Est. Return
+162.55%
10 Year Est. Return
+785.5%
AUM
$15B
AUM Growth
-$64.1M
Cap. Flow
-$674M
Cap. Flow %
-4.48%
Top 10 Hldgs %
8.55%
Holding
1,316
New
82
Increased
373
Reduced
600
Closed
70
Avg Time Held
10.9 quarters
Top 10 Avg Time Held
3.8 quarters
Top 20 Avg Time Held
7.4 quarters

Top Sells

Rank Stock Value
1
CGNX icon
Cognex
CGNX
+$64.3M
2
LDR
Landauer Inc
LDR
+$48.7M
3
MKSI icon
MKS Inc
MKSI
+$39.1M
4
IPGP icon
IPG Photonics
IPGP
+$36.6M
5
CPRT icon
Copart
CPRT
+$34.9M

Sector Composition

Rank Sector Weight
1 Industrials 29.91%
2 Technology 17.71%
3 Consumer Discretionary 16.18%
4 Financials 11.52%
5 Materials 7.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
FSBW icon
1226
FS Bancorp
FSBW
$353M
$6K ﹤0.01%
+212
New +$5.83K
2017 Q4
0 quarters
LAKE icon
1227
Lakeland Industries
LAKE
$98M
$6K ﹤0.01%
+416
New +$6.13K
2017 Q4
0 quarters
MLP icon
1228
Maui Land & Pineapple Co
MLP
$300M
$6K ﹤0.01%
353
-49
-12% -$768
2017 Q3
1 quarter
MRSN icon
1229
DELISTED
Mersana Therapeutics
MRSN
$6K ﹤0.01%
+14
New +$6.11K
2017 Q4
0 quarters
NBN icon
1230
Northeast Bank
NBN
$1.1B
$6K ﹤0.01%
+246
New +$6.22K
2017 Q4
0 quarters
SLP icon
1231
DELISTED
Simulations Plus
SLP
$6K ﹤0.01%
377
+15
+4% +$247
2017 Q3
1 quarter
PVLA icon
1232
Palvella Therapeutics
PVLA
$1.92B
$6K ﹤0.01%
+9
New +$4.18K
2017 Q4
0 quarters
ZIXI
1233
DELISTED
Zix Corporation
ZIXI
$6K ﹤0.01%
+1,365
New +$6.43K
2017 Q4
0 quarters
AKBA icon
1234
Akebia Therapeutics
AKBA
$216M
$5K ﹤0.01%
347
+100
+40% +$1.66K
2017 Q3
1 quarter
INTT icon
1235
inTEST
INTT
$184M
$5K ﹤0.01%
605
-3
-0.5% -$27
2017 Q3
1 quarter
WINA icon
1236
Winmark
WINA
$1.04B
$5K ﹤0.01%
36
+3
+9% +$397
2017 Q3
1 quarter
CUTR icon
1237
DELISTED
Cutera, Inc.
CUTR
$5K ﹤0.01%
119
-3
-2% -$127
2017 Q3
1 quarter
CALA
1238
DELISTED
Calithera Biosciences, Inc
CALA
$5K ﹤0.01%
+33
New +$8.45K
2017 Q4
0 quarters
ANW
1239
DELISTED
Aegean Marine Petroleum Network
ANW
$5K ﹤0.01%
1,250
– –
2015 Q1
11 quarters
DAIO icon
1240
Data I/O
DAIO
$30M
$4K ﹤0.01%
+337
New +$3.99K
2017 Q4
0 quarters
HSTO
1241
DELISTED
Histogen Inc. Common Stock
HSTO
$4K ﹤0.01%
5
+2
+67% +$1.85K
2017 Q3
1 quarter
SGLY icon
1242
Singularity Future Technology
SGLY
$3.78M
$3K ﹤0.01%
+2
New +$3.88K
2017 Q4
0 quarters
NVCN
1243
DELISTED
Neovasc Inc.
NVCN
– –
0
– –
2016 Q1
7 quarters
OPNT
1244
DELISTED
Opiant Pharmaceuticals, Inc. Common Stock
OPNT
$2K ﹤0.01%
+78
New +$2.5K
2017 Q4
0 quarters
AAON icon
1245
Aaon
AAON
$7.05B
$0 ﹤0.01%
2
– –
2013 Q2
18 quarters
ABCB icon
1246
Ameris Bancorp
ABCB
$5.35B
– –
-60,000
Closed -$2.88M –
ALRM icon
1247
Alarm.com
ALRM
$2.76B
– –
-22,000
Closed -$994K –
BTU icon
1248
Peabody Energy
BTU
$3.11B
– –
-526
Closed -$15K –
CARS icon
1249
Cars.com
CARS
$517M
– –
-20,000
Closed -$532K –
CCJ icon
1250
Cameco
CCJ
$37.6B
– –
-24,500
Closed -$237K –

Similar funds

Royce & Associates's Q4 2017 Portfolio in Review

As of Q4 2017, Royce & Associates held 1,316 positions worth $15B, down 0.42% from $15.1B the previous quarter. Its ten largest holdings account for 8.5% of the portfolio.

Royce & Associates withdrew a net $674M in Q4 2017, closing 70 positions and reducing 600 holdings. Its most notable exit was Landauer Inc, an estimated $48.7M position sold in full.

By sector, the portfolio is most concentrated in Industrials at 30% of assets, up from 30% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Royce & Associates opened a new position in Verifone Systems Inc worth $11.2M.

  • Royce & Associates's largest Q4 2017 buy was Verifone Systems Inc: 629,800 shares worth $11.2M.
  • Royce & Associates added most to Fabrinet in Q4 2017, an estimated $28.7M increase.
  • Royce & Associates's biggest Q4 2017 reduction was Cognex, cutting an estimated $64.3M.
  • Royce & Associates fully exited Landauer Inc in Q4 2017, selling an estimated $48.7M.
  • Royce & Associates's ten largest holdings make up 8.5% of its $15B portfolio in Q4 2017.
  • Royce & Associates opened 82 new positions and closed 70 in Q4 2017.
  • Royce & Associates's portfolio value fell 0.42% quarter-over-quarter to $15B.

Based on Royce & Associates's 13F filing for Q4 2017, filed 9 Feb 2018.